2025
SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer
Jiang Z, Bi F, Ge Z, Mansolf M, Hartwich T, Kolesnyk V, Yang K, Park W, Kim D, Grechukhina O, Hui P, Kim S, Yang-Hartwich Y. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer. Cancers 2025, 17: 244. PMID: 39858026, PMCID: PMC11763764, DOI: 10.3390/cancers17020244.Peer-Reviewed Original ResearchEpidermal growth factor receptorOvarian cancerRecurrent tumorsSortilin-related receptor 1Therapeutic efficacy of carboplatinResistant to conventional chemotherapyResistant ovarian cancerMolecular mechanisms of chemoresistanceCancer models in vitroEfficacy of carboplatinRecurrent ovarian cancerOvarian cancer treatmentEffective targeted therapiesMechanisms of chemoresistancePro-tumor functionsGrowth factor receptorXenograft mouse modelConventional chemotherapyStabilization of epidermal growth factor receptorModel in vitroPro-tumorEnhanced chemoresistanceCarboplatin resistanceTherapeutic efficacyFactor receptor
2024
The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma
McCord M, Sears T, Wang W, Chaliparambil R, An S, Sarkaria J, James C, Ruggeri B, Gueble S, Bindra R, Horbinski C. The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma. Neuro-Oncology 2024, 27: 644-651. PMID: 39658092, PMCID: PMC11889708, DOI: 10.1093/neuonc/noae257.Peer-Reviewed Original ResearchMedian survival of miceSurvival of miceMedian survivalIDH wild-type glioblastomaO-6-methylguanine-DNA methyltransferaseExposure to temozolomideAcquired resistance to TMZWild-type glioblastomaPatient-derived xenograftsSensitivity to temozolomidePatient-derived modelsResistance to temozolomideLN229 glioma cellsPatient-derived glioblastomaRecurrent tumorsMGMT deficiencyFractionated RTTemozolomideLow dosesImprove outcomesGlioblastomaEnzyme deficiencyMismatch repairGlioma cellsGBM12Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation
Beddok A, Orlhac F, Rozenblum L, Calugaru V, Créhange G, Dercle L, Nioche C, Thariat J, Marin T, El Fakhri G, Buvat I. Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation. Cancer/Radiothérapie 2024, 28: 597-602. PMID: 39406602, DOI: 10.1016/j.canrad.2024.09.002.Peer-Reviewed Original ResearchPersonalized radiotherapyTumor localizationTreatment planningMedian AUCImaging modalitiesRisk of recurrenceHead and neckImprove treatment precisionPredicting clinical outcomesOptimal treatment planQuantitative imaging biomarkersRecurrent tumorsApplication of radiomicsRecurrent cancerClinical radiotherapyExternal validationClinical outcomesRadiotherapyReirradiationLack of external validationMEDLINE searchTreatment precisionImaging biomarkersImaging protocolTumor204 Laster Interstitial Thermal Therapy for Primary and Recurrent Meningioma: A Prospective and Retrospective Multi-institutional Study
Pugazenthi S, Leidig W, Chiang V, Rodriguez A, Prabhu S, Haskell-Mendoza A, Fecci P, Placantonakis D, Abram S, Lega B, Kim A. 204 Laster Interstitial Thermal Therapy for Primary and Recurrent Meningioma: A Prospective and Retrospective Multi-institutional Study. Neurosurgery 2024, 70: 53-54. DOI: 10.1227/neu.0000000000002809_204.Peer-Reviewed Original ResearchLaser interstitial thermal therapyInterstitial thermal therapyRecurrent meningiomasTreatment optionsTreated with laser interstitial thermal therapyFollow-upResistant to standard therapyRetrospective multi-institutional studyArmamentarium of treatment optionsCentral nervous system tumorsProgression-free survivalGrade 2 meningiomasSeries of patientsPost-procedural complicationsProspective multicenter registryNervous system tumorsMulti-institutional studyThermal therapyRecurrent tumorsOverall survivalStandard therapyMulticenter registryAblation coverageMeningioma treatmentAdult patientsIDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy
Tanner G, Barrow R, Ajaib S, Al-Jabri M, Ahmed N, Pollock S, Finetti M, Rippaus N, Bruns A, Syed K, Poulter J, Matthews L, Hughes T, Wilson E, Johnson C, Varn F, Brüning-Richardson A, Hogg C, Droop A, Gusnanto A, Care M, Cutillo L, Westhead D, Short S, Jenkinson M, Brodbelt A, Chakrabarty A, Ismail A, Verhaak R, Stead L. IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy. Genome Biology 2024, 25: 45. PMID: 38326875, PMCID: PMC10848526, DOI: 10.1186/s13059-024-03172-3.Peer-Reviewed Original ResearchConceptsGBM tumorsTumor microenvironmentNeoplastic cellsResponse to standard treatmentTreatment resistance mechanismsDifferentiated neoplastic cellsSurrounding normal brainResponder subtypesGBM stem cellsAssociated with distinct changesRecurrent tumorsIDHwt glioblastomasTargeted therapyIDH1 mutationStandard treatmentBrain neoplasmsTumorCancer-cellBrain tumorsEffective treatmentNeurotransmitter signalingStem cellsMesenchymal transitionPairs of pre-Subtypes
2023
The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen
Malta T, Sabedot T, Morosini N, Datta I, Garofano L, Vallentgoed W, Varn F, Aldape K, D'Angelo F, Bakas S, Barnholtz-Sloan J, Gan H, Hasanain M, Hau A, Johnson K, Cazacu S, deCarvalho A, Khasraw M, Kocakavuk E, Kouwenhoven M, Migliozzi S, Niclou S, Niers J, Ormond D, Paek S, Reifenberger G, Smitt P, Smits M, Stead L, van den Bent M, Van Meir E, Walenkamp A, Weiss T, Weller M, Westerman B, Ylstra B, Wesseling P, Lasorella A, French P, Poisson L, Woehrer A, Lowman A, deCarvalho A, Castro A, Transou A, Brodbelt A, Hau A, Lasorella A, Golebiewska A, Walenkamp A, Molinaro A, Iavarone A, Ismail A, Westerman B, Ylstra B, Bock C, Ormond D, Brat D, Kocakavuk E, Van Meir E, Barthel F, Varn F, D'Angelo F, Finocchiaro G, Rao G, Zadeh G, Reifenberger G, ngNg H, Kim H, Noushmehr H, Miletic H, Gan H, Datta I, Rock J, Snyder J, Huse J, Connelly J, Barnholtz-Sloan J, Niers J, deGroot J, Akdemir K, Kannan K, Ligon K, Aldape K, Bulsara K, Johnson K, Alfaro K, Poisson L, Garofano L, Stead L, Nasrallah M, Smits M, van den Bent M, Kouwenhoven M, Weller M, Hasanain M, Khasraw M, Gould P, Smitt P, LaViolette P, Tatman P, Wesseling P, French P, Beroukhim R, Verhaak R, Migliozzi S, Niclou S, Bakas S, Kalkanis S, Paek S, Short S, Ghazaleh T, Malta T, Sabedot T, Weiss T, Walbert T, Baid U, Vallentgoed W, Yung W, Verhaak R, Iavarone A, Noushmehr H. The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen. Cancer Research 2023, 84: 741-756. PMID: 38117484, PMCID: PMC10911804, DOI: 10.1158/0008-5472.can-23-2093.Peer-Reviewed Original ResearchConceptsIDHmut gliomasIDHmut tumorsIDHwt gliomasResponse to therapeutic pressureGenes associated with tumor progressionT cell infiltrationLevels of global methylationIDH1 mutation statusAssociated with survivalDNA methylationLoss of DNA methylationGenome-wide DNA methylationRecurrent tumorsIncreased neoangiogenesisMutation statusIDH-wildtypeTherapy resistanceHistological progressionTherapeutic pressureLevel of genome-wide DNA methylationTumor microenvironmentT cellsTreatment regimenTumor adaptationIDH-mutantEvaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. Journal Of Clinical Oncology 2023, 41: 2001-2001. DOI: 10.1200/jco.2023.41.16_suppl.2001.Peer-Reviewed Original ResearchRecurrent brain metastasesImage interpretation criteriaF-fluciclovine PETF-fluciclovine uptakeBrain metastasesF-fluciclovineRadiation therapyDiagnostic performanceHistopathological analysisSUV maxFirst prospective multicenter trialProspective phase 2 trialSolid tumor brain metastasesTumor brain metastasesPhase 2 trialProspective multicenter trialIndependent blinded readersFluciclovine uptakePost-MRIPrimary endpointSecondary endpointsMulticenter trialRadiation necrosisRecurrent tumorsFuture trialsMonitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers
Bellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich T, Harold J, Yang-Hartwich Y, Siegel E, Santin A. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International Journal Of Molecular Sciences 2023, 24: 8873. PMID: 37240216, PMCID: PMC10219151, DOI: 10.3390/ijms24108873.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaCS patientsEarly recurrenceDroplet digital polymerase chain reactionCA 125Serous carcinomaCtDNA testingTime of surgeryTime of recurrenceReliable tumor biomarkersTumour DNA biomarkersCarcinosarcoma patientsUSC patientsRecurrent diseaseOccult diseaseOverall survivalEndometrial cancerAggressive variantInitial treatmentRecurrent tumorsResidual tumorClinical findingsTreatment courseTreatment trialsPIK3CA mutationsLongitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
van Garderen K, Vallentgoed W, Lavrova A, Niers J, de Leng W, Hoogstrate Y, de Heer I, Ylstra B, van Dijk E, Klein S, Draaisma K, Robe P, Verhaak R, Westerman B, French P, van den Bent M, Kouwenhoven M, Kros J, Wesseling P, Smits M. Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort. Neuro-Oncology Advances 2023, 5: vdad149. PMID: 38024241, PMCID: PMC10681663, DOI: 10.1093/noajnl/vdad149.Peer-Reviewed Original ResearchIDH-mutant astrocytomasFluid attenuated inversion recoveryT2-FLAIR mismatchOverall survivalSecond resectionMicrocystic changesT2-FLAIR mismatch signTumor tissueMedian overall survivalGrade 2 tumorsMagnetic resonance imagingSpecific diagnostic markerSurgical resectionFavorable prognosisRecurrent tumorsClinical parametersPrognostic valueFirst resectionHyperintense areasTumor gradeResectionGrade 2AstrocytomasResonance imagingDiagnostic marker
2021
Sequential filtering for clinically relevant variants as a method for clinical interpretation of whole exome sequencing findings in glioma
Ülgen E, Can Ö, Bilguvar K, Akyerli Boylu C, Kılıçturgay Yüksel Ş, Erşen Danyeli A, Sezerman OU, Yakıcıer MC, Pamir MN, Özduman K. Sequential filtering for clinically relevant variants as a method for clinical interpretation of whole exome sequencing findings in glioma. BMC Medical Genomics 2021, 14: 54. PMID: 33622343, PMCID: PMC7903763, DOI: 10.1186/s12920-021-00904-3.Peer-Reviewed Original ResearchConceptsTumor mutational burdenSomatic copy number alterationsWhole-exome sequencing findingsMicrosatellite instabilityGermline variantsClinical interpretationIndividual brain tumorsShort variantRecurrent tumorsMSI incidenceMutational burdenBrain tumorsLoss of heterozygosityPathway enrichment analysisPrimary gliomasClinical settingTumorsWES analysisCopy number alterationsTumor samplesSequencing findingsDiffuse gliomasClinical analysisGliomasChr10 loss
2020
Clinical and genomic factors associated with seizures in meningiomas.
Gupte TP, Li C, Jin L, Yalcin K, Youngblood MW, Miyagishima DF, Mishra-Gorur K, Zhao AY, Antonios J, Huttner A, McGuone D, Blondin NA, Contessa JN, Zhang Y, Fulbright RK, Gunel M, Erson-Omay Z, Moliterno J. Clinical and genomic factors associated with seizures in meningiomas. Journal Of Neurosurgery 2020, 135: 835-844. PMID: 33276341, DOI: 10.3171/2020.7.jns201042.Peer-Reviewed Original ResearchPreoperative seizuresPostoperative seizuresAtypical histologyMultivariate analysisWorse progression-free survivalGenomic subgroupsYale-New Haven HospitalAssociation of seizuresAntiepileptic drug useProgression-free survivalSeizure-free patientsGross total resectionExtent of resectionMultiple risk factorsNF2 mutationsNew Haven HospitalLogistic regression modelsPostoperative radiationSeizure freedomClinical courseSeizure presentationSomatic NF2 mutationsBrain invasionRecurrent tumorsRisk factorsSubtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma
Robinson MH, Vasquez J, Kaushal A, MacDonald TJ, Vega J, Schniederjan M, Dhodapkar K. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. Journal For ImmunoTherapy Of Cancer 2020, 8: e001066. PMID: 32788236, PMCID: PMC7422651, DOI: 10.1136/jitc-2020-001066.Peer-Reviewed Original ResearchConceptsT cell infiltrationHigh-grade gliomasT-cell densityLow-grade tumorsT cellsGlial tumorsTissue-resident memory T cellsTumor-resident T cellsPediatric gliomasTumor-infiltrating T cellsMemory T cellsCancer-related mortalityPediatric glial tumorsSingle-cell mass cytometryExpression of SOX2Stem cell markersImmune controlImmune therapyRecurrent tumorsImmune cellsImmunofluorescence immunohistochemistryPleomorphic xanthoastrocytomaBrain tumorsImmune architectureAdult gliomasLaser interstitial thermal therapy in neuro-oncology applications
Hong CS, Kundishora AJ, Elsamadicy AA, Chiang VL. Laser interstitial thermal therapy in neuro-oncology applications. Surgical Neurology International 2020, 11: 231. PMID: 32874734, PMCID: PMC7451173, DOI: 10.25259/sni_496_2019.Peer-Reviewed Original ResearchLaser interstitial thermal therapyRadiation necrosisInterstitial thermal therapyBrain tumorsNeurosurgical oncologyMultiple intracranial pathologiesRole of LITTStandard craniotomy approachesOptimal patient selectionMetastatic brain tumorsOpen surgical resectionInvasive surgical treatmentLesion-specific characteristicsSymptomatic peritumoral edemaNeuro-oncology applicationsMedical comorbiditiesBrain metastasesSurgical resectionSurgical treatmentPatient selectionRecurrent tumorsTumor characteristicsOpen surgeryCare treatmentCraniotomy approachLaser interstitial thermal therapy for treatment of cerebral radiation necrosis
Hong CS, Beckta JM, Kundishora AJ, Elsamadicy AA, Chiang VL. Laser interstitial thermal therapy for treatment of cerebral radiation necrosis. International Journal Of Hyperthermia 2020, 37: 68-76. PMID: 32672119, DOI: 10.1080/02656736.2020.1760362.Peer-Reviewed Original ResearchConceptsLaser interstitial thermal therapyInterstitial thermal therapyRadiation necrosisRecurrent tumorsCerebral radiation necrosisPeri-operative morbidityBrain metastasis patientsFirst-line therapyAlternative surgical optionReal-time imaging guidanceOpen surgical resectionPersistence of symptomsTreatment of patientsDeep-seated lesionsTissue inflammatory responseAmenable lesionsChronic steroidsBrain metastasesMetastasis patientsSurgical resectionSymptomatic patientsMedical managementSurgical optionsSurgical historyIntracranial pathologyMulticenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE)
Callstrom MR, Woodrum DA, Nichols FC, Palussiere J, Buy X, Suh RD, Abtin FG, Pua BB, Madoff DC, Bagla SL, Papadouris DC, Fernando HC, Dupuy DE, Healey TT, Moore WH, Bilfinger TV, Solomon SB, Yarmohammadi H, Krebs HJ, Fulp CJ, Hakime A, Tselikas L, de Baere T. Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE). Journal Of Thoracic Oncology 2020, 15: 1200-1209. PMID: 32151777, PMCID: PMC9201766, DOI: 10.1016/j.jtho.2020.02.022.Peer-Reviewed Original ResearchConceptsOverall survival ratePulmonary metastasesPercutaneous cryoablationSurvival rateLocal recurrence-free survivalGrade 4 eventsPleural catheter placementMetastatic lung tumorsPhase 2 studyKaplan-Meier methodRecurrence-free survivalRate of pneumothoraxKaplan-Meier estimatesKey inclusion criteriaQuality of lifeComplication eventsExtrapulmonary cancersMetastatic diseasePerformance statusInitial treatmentRecurrent tumorsCatheter placementLung metastasesMulticenter studyCryoablation treatmentMolecular and clonal evolution in recurrent metastatic gliosarcoma
Anderson K, Tan A, Parkinson J, Back M, Kastelan M, Newey A, Brewer J, Wheeler H, Hudson A, Amin S, Johnson K, Barthel F, Verhaak R, Khasraw M. Molecular and clonal evolution in recurrent metastatic gliosarcoma. Molecular Case Studies 2020, 6: a004671. PMID: 31896544, PMCID: PMC6996521, DOI: 10.1101/mcs.a004671.Peer-Reviewed Original ResearchConceptsFirst recurrenceExtracranial metastasesIntracranial tumorsFrontal lobeRight iliac boneLeft frontal lobeOrigin of metastasesFrontal recurrenceMetastatic gliosarcomaConcurrent radiotherapyFurther surgeryFurther recurrenceRecurrent tumorsMetastatic tumorsIliac boneMetastasisRecurrenceTumorsMesenchymal typeSurgeryClonal relationshipRadiotherapyGliosarcomaMolecular profilePelvic bones
2019
Rate of rhinosinusitis and sinus surgery following a minimally destructive approach to endoscopic transsphenoidal hypophysectomy
Rimmer RA, Vimawala S, Chitguppi C, Reilly EK, Graf AE, Fastenberg JH, Evans JJ, Rosen MR, Rabinowitz MR, Nyquist GG. Rate of rhinosinusitis and sinus surgery following a minimally destructive approach to endoscopic transsphenoidal hypophysectomy. International Forum Of Allergy & Rhinology 2019, 10: 405-411. PMID: 31765522, DOI: 10.1002/alr.22482.Peer-Reviewed Original ResearchConceptsFunctional endoscopic sinus surgeryTranssphenoidal hypophysectomyEndoscopic transsphenoidal hypophysectomyChronic rhinosinusitisSinus surgeryNasoseptal flapExcellent long-term patientNasal Outcome Test (SNOT-22) scoresPrior chronic rhinosinusitisRetrospective chart reviewCourse of antibioticsEndoscopic sinus surgeryLong-term patientsOutcome Test scoresPreoperative levelsChart reviewTurbinate lateralizationRecurrent tumorsPrimary indicationSingle institutionPituitary surgeryRhinosinusitisPatientsSurgeryPosterior septectomyATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMAS
Sahebjam S, Forsyth P, Tran N, Etame A, Arrington J, Jaglal M, Mokhtari S, MacAulay R, Wicklund M, Evernden B, Gatewood T, Robinson T, Raval R, Yu M. ATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMAS. Neuro-Oncology 2019, 21: vi5-vi5. PMCID: PMC6847102, DOI: 10.1093/neuonc/noz175.017.Peer-Reviewed Original ResearchGrade 1 elevationExpansion cohortSafety cohortPD-1/PDLStrong pre-clinical evidencesAnti-tumor immune responseRecurrent high-grade gliomaPhase IDose-expansion cohortsGrade 1 anorexiaGrade 1 diarrheaRT treatment fieldUse of corticosteroidsPre-clinical evidenceHigh-grade gliomasPrimary study objectiveCommon toxicitiesEligible ptsPrior RTSecondary endpointsFlat doseRecurrent tumorsGrade IIITumor regressionEfficacy dataSURG-06. LASER INTERSTITIAL THERMAL THERAPY COMPARED TO CRANIOTOMY FOR TREATMENT OF RADIATION NECROSIS OR RECURRENT TUMOR IN BRAIN METASTASES FAILING RADIOSURGERY
Hong C, Deng D, Sujijantarat N, Vera A, Chiang V. SURG-06. LASER INTERSTITIAL THERMAL THERAPY COMPARED TO CRANIOTOMY FOR TREATMENT OF RADIATION NECROSIS OR RECURRENT TUMOR IN BRAIN METASTASES FAILING RADIOSURGERY. Neuro-Oncology Advances 2019, 1: i31-i32. PMCID: PMC7213364, DOI: 10.1093/noajnl/vdz014.141.Peer-Reviewed Original ResearchLaser interstitial thermal therapyProgression-free survivalBrain metastasesRadiation necrosisOverall survivalStereotactic radiosurgeryRecurrent tumorsSingle-institution chart reviewPost-operative salvagePre-operative symptomsSub-group analysisViable alternative treatmentRe-growing tumorSteroid taperNeurological outcomeChart reviewSymptom reliefUnderwent craniotomyTumor lesionsAlternative treatmentCraniotomyLocal controlPatientsMetastasisSmall lesionsCell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara C, Frenster J, Tateishi K, Wakimoto H, Jain R, Riina H, Nicolaides T, Sulman E, Cahill D, Golfinos J, Isse K, Saunders L, Zagzag D, Placantonakis D, Snuderl M, S. A. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research 2019, 25: 1261-1271. PMID: 30397180, PMCID: PMC7365589, DOI: 10.1158/1078-0432.ccr-18-2312.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedBenzodiazepinonesBrainDNA MethylationFemaleGene Expression Regulation, NeoplasticGenotypeGliomaHumansImmunoconjugatesIntracellular Signaling Peptides and ProteinsIsocitrate DehydrogenaseLigandsMaleMembrane ProteinsMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalReceptors, NotchRNAConceptsGlioma molecular subtypesAntibody-drug conjugatesMolecular subtypesCell surface tumor-associated antigensTumor-associated antigensWild-type glioblastomaAntigen-dependent mannerLow-grade gliomasRova-TRecurrent tumorsDLL3 expressionRovalpituzumab tesirineNontumor brain tissuesNontumor brainMutant gliomasTherapeutic strategiesCell viability assayGliomaRNA levelsDLL3TumorspheresTherapeutic targetIHCTCGA dataWild-type
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply